Pulmonary Mucormycosis: Beyond Classic COVID-19-Associated Fungal Infections.

Publication date: Jan 01, 2024

Coronavirus disease 2019 (COVID-19) is often linked to a broad range of opportunistic bacterial and fungal infections. The second wave of the COVID-19 pandemic has witnessed an unprecedented surge in mucormycosis cases, predominantly in India, while the disease remained relatively rare in Europe. The authors describe the case of a 62-year-old female patient admitted to the hospital for consolidation therapy with chemotherapy as a part of the treatment protocol for acute myeloid leukemia. During hospitalization, she was diagnosed with nosocomial COVID-19, which later progressed to respiratory deterioration. COVID-19 with bacterial superinfection was presumed, leading to the initiation of empirical antibiotic therapy. A bronchoscopy was performed several days later due to a lack of improvement, revealing an infection by the Rhizopus microsporus complex. Despite antifungal treatment, the patient experienced an unfavorable clinical course and ultimately died. Given the high index of suspicion required to diagnose pulmonary mucormycosis, which can lead to delays in appropriate treatment and increase the burden of disease, the authors are aiming to enhance its awareness.

Concepts Keywords
Bacterial covid 19
Chemotherapy covid-19
Coronavirus covid-19-associated mucormycosis
Rare mucor
Superinfection pulmonary mucormycosis


Type Source Name
disease MESH Mucormycosis
disease MESH COVID-19
disease MESH Fungal Infections
disease VO protocol
disease MESH acute myeloid leukemia
pathway KEGG Acute myeloid leukemia
disease MESH superinfection
disease VO LACK
disease MESH infection
disease MESH clinical course

Original Article

(Visited 1 times, 1 visits today)